#1 Clinical Trials Search in Europe

Emicizumab

Emicizumab is a novel bispecific antibody being studied as a treatment for hemophilia A in several clinical trials. These trials are evaluating the efficacy, safety, and pharmacokinetics of emicizumab in patients with hemophilia A, both with and without factor VIII inhibitors. The studies are examining different dosing regimens and patient populations, including adults, adolescents and young children. Key outcomes being assessed include bleeding rates, quality of life measures, and safety parameters.

Table of Contents

What is Emicizumab?

Emicizumab is a groundbreaking medication used to treat hemophilia A, a rare bleeding disorder. It’s also known by the brand name Hemlibra and other scientific names like RO5534262, RG6013, and ACE910[1]. Emicizumab is a type of drug called a monoclonal bispecific antibody, which means it’s a specially designed protein that can bind to two different targets in the body[2].

How Does Emicizumab Work?

In people with hemophilia A, a protein called factor VIII (FVIII) is missing or doesn’t work properly. This protein is crucial for blood clotting. Emicizumab works by mimicking the function of factor VIII. It binds to and brings together two other clotting factors, activated factor IX and factor X, which helps the blood to clot normally[2]. This unique mechanism allows emicizumab to prevent bleeding in people with hemophilia A, even if they have developed antibodies (called inhibitors) against traditional factor VIII treatments.

Conditions Treated by Emicizumab

Emicizumab is primarily used to treat:

  • Hemophilia A: This includes both severe and moderate forms of the condition[3].
  • Hemophilia A with inhibitors: This refers to patients who have developed antibodies against traditional factor VIII treatments[1].
  • Acquired Hemophilia A: A rare form of hemophilia that develops later in life[4].

Interestingly, research is also being conducted to explore the use of emicizumab in treating severe Von Willebrand Disease, another bleeding disorder[2].

How is Emicizumab Administered?

One of the major advantages of emicizumab is its method of administration. Unlike many other treatments for hemophilia that require frequent intravenous infusions, emicizumab is given as a subcutaneous injection (an injection just under the skin)[1]. This makes it much easier for patients to use at home.

The typical dosing schedule includes:

  1. Loading dose: 3 mg per kg of body weight once a week for the first 4 weeks.
  2. Maintenance dose: After the first 4 weeks, patients can choose from several options:
    • 1.5 mg/kg once a week
    • 3 mg/kg every 2 weeks
    • 6 mg/kg every 4 weeks

This flexible dosing schedule allows patients and their doctors to choose the most convenient option[5].

Efficacy of Emicizumab

Clinical trials have shown that emicizumab is highly effective in preventing bleeding episodes in people with hemophilia A. Key findings include:

  • Significant reduction in annualized bleeding rates (ABR): This means patients experienced fewer bleeding episodes per year while on emicizumab[1].
  • Effective in patients with and without inhibitors: Emicizumab works well even in patients who have developed resistance to traditional factor VIII treatments[6].
  • Long-lasting effect: The medication maintains its effectiveness with less frequent dosing compared to traditional treatments[5].

Safety and Side Effects

Overall, emicizumab has shown a good safety profile in clinical trials. However, like all medications, it can have side effects. The most common side effects reported include:

  • Injection site reactions (redness, itching, or pain where the injection is given)
  • Headache
  • Joint pain
  • Flu-like symptoms

More serious but rare side effects that have been observed include:

  • Thrombotic events (formation of blood clots)
  • Thrombotic microangiopathy (a condition affecting small blood vessels)

It’s important to note that these serious side effects are rare and often associated with the use of certain other blood clotting products alongside emicizumab[1][7].

Impact on Quality of Life

Emicizumab has shown significant improvements in patients’ quality of life. Studies have used various questionnaires to measure this, including:

  • Haem-A-QoL (Hemophilia-Specific Quality of Life Questionnaire for Adults)
  • Haemo-QoL-SF (Hemophilia-Specific Quality of Life Questionnaire for Children)
  • EQ-5D-5L (a general health status questionnaire)

Patients reported improvements in physical health, ability to participate in activities, and overall well-being. Many patients also preferred emicizumab treatment over their previous treatments[1][5].

Ongoing Research

Research on emicizumab is ongoing, with several studies exploring its use in different patient groups and scenarios. Some areas of current research include:

  • Use in very young children (from birth to 12 months old)[7]
  • Long-term effects on joint health[3]
  • Use in patients undergoing minor surgical procedures[8]
  • Potential applications in other bleeding disorders like Von Willebrand Disease[2]

These ongoing studies will help to further our understanding of emicizumab and potentially expand its use to benefit more patients with bleeding disorders.

Aspect Details
Drug Emicizumab (also known as Hemlibra, ACE910, RO5534262, RG6013)
Condition Hemophilia A (with and without factor VIII inhibitors)
Administration Subcutaneous injection
Dosing Regimens Various, including weekly, every 2 weeks, and every 4 weeks
Patient Populations Adults, adolescents, children, including very young children
Primary Outcomes Annualized bleeding rates, quality of life measures, joint health scores
Safety Assessments Adverse events, thromboembolic events, injection site reactions, anti-drug antibodies
Study Durations 52 weeks to several years for long-term follow-up

FAQ

  • What is emicizumab? Emicizumab is a bispecific antibody that mimics the function of factor VIII to help blood clot in people with hemophilia A. It is given as a subcutaneous injection.
  • Who is being studied in these clinical trials? The trials are studying patients with hemophilia A of various ages, including adults, adolescents, and young children. Some trials focus on patients with factor VIII inhibitors, while others include patients without inhibitors.
  • How is emicizumab administered? Emicizumab is given as a subcutaneous injection, typically starting with weekly loading doses followed by maintenance doses given weekly, every 2 weeks, or every 4 weeks depending on the specific trial.
  • What are the main outcomes being measured? Key outcomes include annualized bleeding rates, quality of life scores, joint health assessments, safety/adverse events, and pharmacokinetic measures of emicizumab levels in the blood.
  • How long do these clinical trials last? The trials have varying durations, but many follow patients for at least 52 weeks, with some having longer-term follow-up periods of several years to assess long-term efficacy and safety.

Ongoing Clinical Trials on Emicizumab

  • Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +2

  • Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

    Recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria Croatia Finland Germany Norway Spain +1

  • Study on Personalized Dosing of Emicizumab for Patients with Congenital Hemophilia A

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

  • Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months)

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy Spain

  • Study on Health, Activity, and Joint Outcomes in Patients Aged 13-69 with Severe or Moderate Hemophilia A Using Emicizumab

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Spain

Glossary

  • Hemophilia A: A genetic bleeding disorder caused by a deficiency in clotting factor VIII.
  • Factor VIII inhibitors: Antibodies that neutralize factor VIII, making standard factor VIII replacement therapy ineffective.
  • Annualized bleeding rate (ABR): The number of bleeding episodes a patient experiences per year, used to assess treatment efficacy.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized and eliminated by the body.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Loading dose: An initial higher dose of medication given at the start of treatment to rapidly achieve therapeutic levels.
  • Maintenance dose: The regular dose given to maintain therapeutic levels of a medication after the loading dose period.
  • Bispecific antibody: An artificially created antibody that can bind to two different types of antigens.
  • Quality of life (QoL): A measure of an individual's wellbeing and ability to carry out daily activities.
  • Adverse event: Any unfavorable medical occurrence in a clinical trial participant, whether or not considered related to the study treatment.

References

  1. https://clinicaltrials.gov/study/NCT03191799
  2. https://clinicaltrials.gov/study/NCT05500807
  3. https://clinicaltrials.gov/study/NCT05181618
  4. https://clinicaltrials.gov/study/NCT05345197
  5. https://clinicaltrials.gov/study/NCT03020160
  6. https://clinicaltrials.gov/study/NCT02795767
  7. https://clinicaltrials.gov/study/NCT04431726
  8. https://clinicaltrials.gov/study/NCT03361137